- Conditions
- Interstitial Lung Disease
- Interventions
- Not listed
- Lead sponsor
- Pulmonary Care and Research Collaborative Limited
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 409–432
of 597
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Granulomatosis With Polyangiitis (Wegener's), Granulomatosis With Polyangiitis, Wegener's Granulomatosis, ANCA-Associated Vasculitis
- Interventions
- Abatacept, placebo
- Drug
- Lead sponsor
- University of South Florida
- Other
- Eligibility
- 15 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Tampa, Florida • Kansas City, Kansas + 7 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- HRCT, Blood Draw
- Diagnostic Test
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 40 Years to 101 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Antimicrobial therapy: Co-trimoxazole or Doxycycline, No Intervention: Standard of Care
- Drug · Other
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 513 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Sacramento, California + 22 more
- Conditions
- Idiopathic Inflammatory Myopathies
- Interventions
- Rapcabtagene autoleucel, Active Comparator Option
- Biological · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Zephyrhills, Florida • Augusta, Georgia + 7 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Therapeutic Plasma Exchange, Rituximab, Intravenous immunoglobulin, Treatment as Usual
- Other · Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Chicago, Illinois • Kansas City, Kansas + 4 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- 20mM sodium pyruvate nasal spray, Saline Placebo control nasal spray
- Drug · Other
- Lead sponsor
- Cellular Sciences, inc.
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Hialeah Gardens, Florida
- Conditions
- Pulmonary Fibrosis
- Interventions
- A wearable cough monitoring device, the Strados Labs RESPᵀᴹ sensor, with an accompanying mobile application (App) for data collection
- Device
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 4
- States / cities
- Lakewood, Colorado • Reno, Nevada • Winston-Salem, North Carolina + 1 more
- Conditions
- Systemic Sclerosis, Diffuse Sclerosis Systemic, Interstitial Lung Disease, Pulmonary Hypertension
- Interventions
- Cyclophosphamide, Mesna, Rituximab, Alemtuzumab, Thiotepa, GM-CSF, Intravenous immunoglobulin, Total Body Irradiation, Anti Thymocyte Globulin
- Drug · Radiation
- Lead sponsor
- Paul Szabolcs
- Other
- Eligibility
- 8 Years to 60 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 2
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Nintedanib
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 66 Years and older
- Enrollment
- 1,798 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Milton, Massachusetts
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- 12-week mHealth home exercise prescription
- Behavioral
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF)
- Interventions
- Placebo for AZD8965, AZD8965 low dose, AZD8965 medium dose, AZD8965 high dose
- Other · Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 359 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 30 more
- Conditions
- Idiopathic Pulmonary Fibrosis, IPF
- Interventions
- Tazarotene (GRI-0621), Placebo
- Drug
- Lead sponsor
- GRI Bio Operations, Inc.
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 5
- States / cities
- Newport Beach, California • Jacksonville, Florida • The Bronx, New York + 2 more
- Conditions
- Bronchogenic Carcinoma, Chronic Granulomatous Disease, Job's Syndrome, Mycobacterium Infection, Wegener's Granulomatosis
- Interventions
- virtual bronchoscopy
- Device
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- Not listed
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2001
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Interstitial Lung Disease
- Interventions
- Not listed
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 400 participants
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Pulmonary Disease, Chronic Obstructive, Pulmonary Fibrosis, Cough
- Interventions
- interferon-alpha lozenges, placebo lozenges
- Drug
- Lead sponsor
- Ainos, Inc. (f/k/a Amarillo Biosciences Inc.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Lubbock, Texas
- Conditions
- Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma, Oligodendroglioma, Childhood, Anaplastic Oligodendroglioma, Glioblastoma, Pilocytic Astrocytoma, Giant Cell Astrocytoma, Pleomorphic Xanthoastrocytoma, Anaplastic Pleomorphic Xanthoastrocytoma, Angiocentric Glioma, Chordoid Glioma of Third Ventricle, Gangliocytoma, Ganglioglioma, Anaplastic Ganglioglioma, Dysplastic Gangliocytoma of Cerebrellum, Desmoplastic Infantile Astrocytoma and Ganglioglioma, Papillary Glioneuronal Tumor, Rosette-forming Glioneuronal Tumor, Central Neurocytoma, Extraventricular Neurocytoma, Cerebellar Liponeurocytoma, Neurofibromatosis Type 1
- Interventions
- dabrafenib, trametinib
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 1 Year to 99 Years
- Enrollment
- 163 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Washington D.C., District of Columbia • Miami, Florida + 8 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- QAX576
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 6
- States / cities
- Denver, Colorado • Atlanta, Georgia • New Orleans, Louisiana + 3 more
- Conditions
- Pulmonary Fibrosis
- Interventions
- aerosol interferon-gamma
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2018
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF), Sarcoidosis Lung, Pulmonary Hypertension, Usual Interstitial Pneumonia
- Interventions
- Not listed
- Lead sponsor
- Cosmos Rx, Inc
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Norfolk, Virginia
- Conditions
- Pulmonary Sarcoidosis
- Interventions
- XTMAB-16
- Drug
- Lead sponsor
- Xentria, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 5
- States / cities
- Denver, Colorado • Chicago, Illinois • Greenville, North Carolina + 2 more
- Conditions
- Granulomatosis With Polyangiitis, Wegener Granulomatosis
- Interventions
- Trimethoprim Sulfamethoxazole
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Progressive Pulmonary Fibrosis
- Interventions
- BMS-986278, BMS-986278 Placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 1,057 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 81
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 70 more
- Conditions
- Advanced Malignant Solid Neoplasm, Malignant Solid Neoplasm, Recurrent Ependymoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Primary Central Nervous System Neoplasm, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Refractory Ependymoma, Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Primary Central Nervous System Neoplasm, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Wilms Tumor
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan, Computed Tomography, Ensartinib, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Pharmacological Study, Positron Emission Tomography, Radionuclide Imaging, X-Ray Imaging
- Procedure · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 122
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 95 more